The global Radiopharmaceuticals Third-Party Logistics Market is witnessing remarkable growth as healthcare systems increasingly adopt nuclear medicine for diagnostics and targeted therapies. The demand for specialized logistics services capable of transporting radioactive materials safely and efficiently is growing significantly across developed and emerging economies. Rising cancer...

Global Radiopharmaceutical Market: Size, Share, Trends, and Industry Growth Analysis Market Overview and Growth Snapshot The Global Radiopharmaceutical Market is experiencing significant growth, driven by the increasing adoption of nuclear medicine for diagnostic and therapeutic applications. Radiopharmaceuticals are radioactive compounds used in imaging techniques such as PET (positron...

The North America diagnostic radiopharmaceutical market is expected to remain a major contributor to the global industry through 2034, supported by the region’s advanced healthcare infrastructure, increasing adoption of molecular imaging, and growing demand for precise disease diagnosis. Diagnostic radiopharmaceuticals are increasingly used in positron emission tomography (PET) and...

The nuclear medicine market is entering a period of steady expansion as healthcare systems increasingly adopt precision diagnostics and targeted therapies. The market was valued at USD 21.3 billion in 2025 and is projected to reach USD 38.2 billion by 2033, growing at a 6.8% CAGR from 2026 to 2033. The market is estimated to reach USD 24.1 billion in 2026. Growth is being supported by a robust...

The Radiopharmaceutical Market growth is fundamentally altering the competitive dynamics of the pharmaceutical and medical device industries as nuclear medicine establishes itself as a distinct and rapidly expanding therapeutic category. Traditional pharmaceutical development models, which focus on small molecule drugs and biologics with extended shelf lives and conventional distribution...

Lutetium-177 PSMA radioligand therapy — the targeted radionuclide treatment delivering beta-emitting Lu-177 directly to prostate-specific membrane antigen-expressing prostate cancer cells — represents the most commercially significant radiopharmaceutical theranostics launch in the market's history, with the Radiopharmaceutical Theranostics Market reflecting Lu-177 PSMA as the...